Literature DB >> 20034417

The luteal phase after 3 decades of IVF: what do we know?

H M Fatemi1.   

Abstract

The luteal phases of all stimulated IVF cycles are abnormal. The main cause of the luteal phase defect (LPD) observed in stimulated IVF cycles is related to the multifollicular development achieved during ovarian stimulation. This may be related to the supra-physiological concentrations of steroids secreted by a high number of corpora lutea during the early luteal phase, which directly inhibit LH release via negative feedback actions at the hypothalamic-pituary axis level, rather than a central pituitary cause or steroidogenic abnormality in the corpus luteum. To correct the LPD in stimulated IVF cycles, human chorionic gonadotrophin (HCG) or progesterone can be administered. HCG is associated with a greater risk of ovarian hyperstimulation syndrome. Natural micronized progesterone is not efficient if taken orally. Vaginal and intramuscular progesterone do have comparable implantation, clinical pregnancy and delivery rates. However, because of severe side effects, intramuscular progesterone administration should be avoided.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20034417

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  20 in total

Review 1.  Novel Concepts for Inducing Final Oocyte Maturation in In Vitro Fertilization Treatment.

Authors:  Ali Abbara; Sophie A Clarke; Waljit S Dhillo
Journal:  Endocr Rev       Date:  2018-10-01       Impact factor: 19.871

Review 2.  Progesterone and the luteal phase: a requisite to reproduction.

Authors:  Tolga B Mesen; Steven L Young
Journal:  Obstet Gynecol Clin North Am       Date:  2015-01-05       Impact factor: 2.844

Review 3.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

4.  Administration effects of single-dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta-analysis of randomized controlled trials.

Authors:  Mengling Song; Chunlian Liu; Rong Hu; Feimiao Wang; Zhenghao Huo
Journal:  Exp Ther Med       Date:  2019-11-27       Impact factor: 2.447

5.  Evolution of serum progesterone levels in the very early luteal phase of stimulated IVF/ICSI cycles post hCG trigger: a proof of concept study.

Authors:  Carol Coughlan; R Vitorino; L Melado; S Digma; J Sibal; R Patel; B Lawrenz; H Fatemi
Journal:  J Assist Reprod Genet       Date:  2022-04-07       Impact factor: 3.357

6.  Apoptosis is increased and cell proliferation is decreased in out-of-phase endometria from infertile and recurrent abortion patients.

Authors:  Gabriela F Meresman; Carla Olivares; Susana Vighi; Margarita Alfie; Marcela Irigoyen; Juan J Etchepareborda
Journal:  Reprod Biol Endocrinol       Date:  2010-10-22       Impact factor: 5.211

7.  Can steroidal ovarian suppression during the luteal phase after oocyte retrieval reduce the risk of severe OHSS?

Authors:  Ya-Qin Wang; Jin Luo; Wang-Min Xu; Qin-Zhen Xie; Wen-Jie Yan; Geng-Xiang Wu; Jin Yang
Journal:  J Ovarian Res       Date:  2015-09-23       Impact factor: 4.234

8.  Single-Dose Versus Multiple-Dose GnRH Agonist for Luteal-Phase Support in Women Undergoing IVF/ICSI Cycles: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Yang Liu; Yanzhi Wu; Zhengmei Pan; Fangjie Jiang; Youhui Lu; Yushi Meng
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

9.  Vaginal micronized progesterone capsule versus vaginal progesterone gel for lutheal support in normoresponder IVF/ICSI-ET cycles.

Authors:  Kenan Sofuoglu; Ismet Gun; Sadik Sahin; Okan Ozden; Oktay Tosun; Mustafa Eroglu
Journal:  Pak J Med Sci       Date:  2015 Mar-Apr       Impact factor: 1.088

10.  Luteal phase support for in vitro fertilization/intracytoplasmic sperm injection fresh cycles: a systematic review and network meta-analysis.

Authors:  Hanglin Wu; Songying Zhang; Xiaona Lin; Shasha Wang; Ping Zhou
Journal:  Reprod Biol Endocrinol       Date:  2021-07-06       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.